An interventional study of GPOU in Colorectal Cancer and Surgery, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 4 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.
Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 294th largest by planned enrollment of the 464 interventional ones that give a count, is one of 26 that started in 2023, is one of 116 with no phase, reaches primary completion later than 123 of the 164 other live ones, and was the 483rd registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18+
Centre Antoine Lacassagne · Sites in France
Ages 18–75
Verastem, Inc. · Sites in France, United States, Australia and 2 more countries
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
583 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 116 · Phase 2 207 · Phase 3 97 · Phase 4 6
First in 1993; this study’s year is marked. 26 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 152 across the 464 interventional studies, 274 across the 103 observational. Of the 358 that completed or were terminated, 107 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
224 of 583 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 7 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520578Phase 3University Hospital, CaenEFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) | 2027-03-24 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 583 studies in Colorectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Health establishments encourage the development of specific care pathways for the elderly by supporting Geriatric Peri-Operative Units (GPOU). Indeed, this shared care model has shown a clear reduction in mortality and the number of re-hospitalizations in patients 6 months after their care. The multidisciplinary approach of global management of the patient in the perioperative period aims to reduce surgical stress as well as the rapid restoration of previous physical and psychic abilities. Colorectal surgery, the main treatment for stage I to III colon cancer, is a morbid surgery. Despite numerous efficacy data on improved rehabilitation after colorectal surgery, care programs are not specific to the geriatric population and geriatric assessment criteria to describe the functional status of patients are not commonly used. The study investigators wish to evaluate the impact of GPOU treatment following colorectal surgery, on the evolution of several clinical parameters such as: functional status, morbidity mortality, quality of life, and lifestyle. The study investigators hypothesize that management in the GPOU for colorectal cancer surgery in patients aged 70 and over will improve functional status at 3 months, in comparison with traditional management. The proposed intervention should also lead to an improvement in patient satisfaction with care, complications and re-hospitalizations, nutritional status, lifestyle and patient survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Classical management in the digestive surgery department
Treatment is carried out in Peri-Operative Geriatrics Unit to optimize specific geriatric care
Other: GPOU
Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure. Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report
Change in functional status after colorectal cancer surgery between groups
Instrumental Activities of Daily Living (IADL) score (score 0-8)
Time frame: Baseline and Month 3
Change in functional status between groups
Instrumental Activities of Daily Living (IADL) score (score 0-8)
Time frame: Baseline and Month 6
Change in basic functional status between groups
Katz index of independence in Activities of Daily Living scale (ADL) (score 0-6)
Time frame: Baseline, hospital discharge (an average of 10 days), Month 3, and Month 6
Change in patient motor ability between groups
Time Up and Go test (Score 0-3 for each item, time in seconds)
Time frame: Baseline, Month 3
Patient satisfaction with care between groups
EORTC SATisfaction with IN-PATient cancer care (IN-PATSAT) 32 questionnaire (Score 32-160)
Time frame: Hospital discharge (an average of 10 days)
Length of hospital stay between groups
Days
Time frame: Hospital discharge (an average of 10 days)
The number of medical complications during hospitalization between groups
Number of following events: diabetes decompensation, cardiorespiratory decompensation, pulmonary and urinary infections, acute renal failure, anemia. Aggravation of: confusion, pelvic exoneration disorders, fall, bedsores.
Time frame: Hospital discharge (an average of 10 days)
The distribution of surgical complications between groups
Gravity of surgical complications according to the Clavien Dindo classification
Time frame: Hospital discharge (an average of 10 days)
The distribution of surgical complications between groups
Gravity of surgical complications according to the Clavien Dindo classification
Time frame: Month 1
Destination of patients on discharge from hospital between groups
Classified as: home / nursing home or institutionalization / transfer to Aftercare and Rehabilitation / transfer to another service / none (death during hospitalization).
Time frame: Hospital discharge (an average of 10 days)
The change in the patient's weight between groups
Percent change in Kg
Time frame: Baseline and Month 3
Patient quality of life between groups
EORTC-QLQ-C30 questionnaire score (Score 0-100)
Time frame: Month 3
Patient quality of life between groups
EORTC-QLQ-C30 questionnaire score (Score 0-100)
Time frame: Month 6
Change in the patient's place of abode between groups
Rate (%) of patients living at home/in nursing home/residential home
Time frame: Month 1, Month 3 and Month 6
Overall survival between groups.
Percentage of immediate mortality (during the hospital stay)
Time frame: Month 1
Overall survival between groups.
Percentage of immediate mortality (during the hospital stay)
Time frame: Month 3
Overall survival between groups.
Percentage of immediate mortality (during the hospital stay)
Time frame: Month 6
The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups
Re-hospitalization in the month following discharge from hospital: yes/no.
Time frame: Month 1
Started Sep 2023 (actual). Primary completion is estimated for Oct 2028, 61 months after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 61 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →